Literature DB >> 15303459

Azithromycin and warfarin interaction.

Sarah P Shrader1, Joli D Fermo, Amy L Dzikowski.   

Abstract

A 57-year-old Caucasian woman came to the clinic with symptoms of an upper respiratory tract infection. She was treated with a 5-day course of oral azithromycin 500 mg on day 1, then 250 mg/day for 4 days. During this period, the patient decreased her cigarette smoking from 1 pack/day to 1 pack every 3 days. No additional confounding variables were present. Two days after the completion of therapy, her international normalized ratio (INR) was 8.32. Six case reports documented in the literature have suggested an azithromycin-warfarin interaction with a resultant increase in INR. Many confounding variables existed in each of these cases, such as hepatic dysfunction, poor appetite, and concomitant drugs that resulted in an increased anticoagulant response. We report a case that involved only one potential confounding variable. Continued documentation of azithromycin-warfarin interactions is valuable considering no mention of this drug interaction exists in most tertiary references and in the package insert for azithromycin, the demonstration that no drug interaction occurred in a retrospective review of 52 cases, and the widespread use of azithromycin in the community. Clinicians should be mindful when prescribing azithromycin in combination with warfarin, and INR values should be monitored.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15303459     DOI: 10.1592/phco.24.9.945.36100

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.

Authors:  Jacques Baillargeon; Holly M Holmes; Yu-Li Lin; Mukaila A Raji; Gulshan Sharma; Yong-Fang Kuo
Journal:  Am J Med       Date:  2012-02       Impact factor: 4.965

Review 2.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 3.  Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

Authors:  Steven D Brown
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.